3M Health Care Launches New Chromatographic Clarifier
The 3M Harvest RC Chromatographic Clarifier, BT500 is the latest addition to the company’s chromatographic clarifier portfolio.
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com
On Nov. 15, 2023, 3M announced the latest addition to its chromatographic clarifier portfolio. The Harvest RC Chromatographic Clarifier, BT500 is a 500-mL size, single-use chromatographic clarifier for monoclonal antibodies, recombinant proteins, and biologics. According to the company, the BT500 can produce predictive yield samples in 10 minutes, based on 5–8% packed cell volume (PCV) culture.
The BT500 offers a lab-scale solution for high purity and recovery “representative of a commercial scale process for clarification,” without the need for a centrifuge. The bottle-top vacuum technology delivers high product recoveries and DNA reduction (< 500ppb—based on 5–8% PCV culture) through a streamlined workflow, according to the company.
The 3M Harvest RC Chromatographic Clarifier portfolio is a set of fiber chromatography clarification devices that use proprietary fibrous chromatography media to deliver a single-stage purification solution for recombinant protein therapeutic manufacturing, which streamlines a multi-stage harvest clarification operation into a single-stage operation.
“Adding 3M Harvest RC Chromatographic Clarifier, BT500 to our product portfolio provides a much-needed solution for customers looking to maximize efficiency in the lab setting, allowing them to better keep pace with the accelerated industry demand,” said David Chau, bioprocess applications specialist at 3M Separation and Purification Sciences, in a press release.“ The Harvest RC Chromatographic Clarifier portfolio enables process intensification, yield improvements, and greater contaminant reduction compared to legacy methods. This new rapid testing capability extends even more opportunity for efficient workflows and exceptional clarity in bioprocess manufacturing.”
Source: 3M
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
